Emcure Pharmaceuticals Ltd. appears to have thrown down the gauntlet to Eisai Co. Ltd. with the launch on the Indian market of its “cost-effective” generic version of the Japanese firm’s Halaven (eribulin) for the treatment of metastatic breast cancer (MBC).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?